

Page 352

UNITED STATES PATENT AND TRADEMARK OFFICE  
-----  
BEFORE THE PATENT TRIAL AND APPEAL BOARD  
-----  
NALOX-1 PHARMACEUTICALS, LLC  
Petitioner  
v.  
ADAPT PHARMA OPERATIONS LIMITED, and  
OPIANT PHARMACEUTICALS, INC.,  
Patent owners  
-----  
Case No. IPR2019-00685  
Case No. IPR2019-00688  
Case No. IPR2019-00694  
  
REMOTE VIDEO CONFERENCE  
CONTINUED VIDEOTAPED DEPOSITION OF  
MAUREEN DONOVAN, Ph.D., Volume 2  
Swisher, Iowa  
April 17, 2020, 9:39 a.m.  
  
Reported by: Michele E. Eddy, RPR, CRR, CLR  
  
-----  
DIGITAL EVIDENCE GROUP  
1730 M Street, NW, Suite 812  
Washington, D.C. 20036  
(202) 232-0646

Page 353

A P P E A R A N C E S

1  
2  
3 ON BEHALF OF THE PETITIONER:  
4 RICHARD J. BERMAN, ESQUIRE  
5 YELEE Y. KIM, ESQUIRE  
6 JOSHUA H. HARRIS, ESQUIRE  
7 Arent Fox LLP  
8 1717 K Street, Northwest  
9 Washington, D.C. 20036  
10 Telephone: (202) 857-6000  
11 Richard.Berman@arentfox.com  
12 Yelee.Kim@arentfox.com  
13 Joshua.Harris@arentfox.com  
14  
15  
16  
17  
18  
19  
20  
21  
22

Page 354

1 ATTENDANCE, Continued  
2  
3 ON BEHALF OF THE PATENT OWNER ADAPT PHARMA OPERATIONS:  
4 JESSAMYN S. BERNIKER, ESQUIRE  
5 KEVIN HOAGLAND-HANSON, ESQUIRE  
6 ANA C. REYES, ESQUIRE  
7 JESSICA PALMER RYEN, ESQUIRE  
8 ANTHONY SHEH, ESQUIRE  
9 Williams & Connolly LLP  
725 Twelfth Street, Northwest  
10 Washington, D.C. 20005  
11 Telephone: (202) 434-5000  
12 JBerniker@wc.com  
13 KHoagland-Hanson@wc.com  
14 AReyes@wc.com  
15 JRyen@wc.com  
16 ASheh@wc.com  
17  
18 - AND -  
19  
20 JESSICA TYRUS MACKAY, ESQUIRE  
21 ANN K. KOTZE, ESQUIRE  
22 Green, Griffith & Borg-Breen, LLP  
676 N. Michigan Avenue, #3900  
Chicago, Illinois 60611  
Telephone: (312) 883-8000  
jmackey@greengriffith.com  
akotze@greengriffith.com

Page 355

E X A M I N A T I O N I N D E X

	PAGE
EXAMINATION BY MS. BERNIKER	356

E X H I B I T S

(None marked)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

Page 356

1 PROCEEDINGS  
 2 April 17, 2020  
 3 ---  
 4 THE VIDEOGRAPHER: The time is  
 5 9:39 a.m., Central Time, on April 17th, 2020.  
 6 This is video 1 of volume 2 of the continued video  
 7 deposition of Dr. Maureen Donovan.  
 8 Will the court reporter please  
 9 readminister the oath, and counsel for appearances  
 10 will be noted on the stenographic record.  
 11 ---  
 12 MAUREEN DONOVAN, Ph.D.,  
 13 having been duly sworn, testified as follows:  
 14 EXAMINATION BY COUNSEL FOR PATENT OWNER ADAPT PHARMA  
 15 BY MS. BERNIKER:  
 16 Q Good morning, Doctor.  
 17 A Good morning.  
 18 Q How are you today?  
 19 A I'm fine, thanks.  
 20 Q Great, great.  
 21 So you understand that you're under oath  
 22 this morning, right?

Page 357

1 A Yes, I do.  
 2 Q And just like you were the last time you  
 3 testified in this proceeding?  
 4 A Yes.  
 5 Q And just like you were when you  
 6 submitted the declarations that you submitted in  
 7 this proceeding?  
 8 A Yes, that's my understanding.  
 9 Q Okay. And I believe you testified to  
 10 this earlier, but you do not have clinical  
 11 expertise in the administration of opioid  
 12 antagonists to treat opioid overdoses, right?  
 13 A I don't have a license to practice as a  
 14 physician. I have -- I was licensed as a  
 15 pharmacist at one point in time in my career.  
 16 Q You don't hold yourself out as having  
 17 clinical expertise, right, Doctor?  
 18 A I have -- I don't have a license to  
 19 practice medicine, but I had a license to practice  
 20 pharmacy.  
 21 Q Do you hold yourself out as a clinical  
 22 expert?

Page 358

1 A I have knowledge of clinical treatments,  
 2 but I don't have a license to practice medicine.  
 3 Q And you wouldn't call yourself a  
 4 clinician, right?  
 5 A No, I don't have a license to practice.  
 6 Q Okay. And in your first declaration you  
 7 characterized yourself as testifying from the  
 8 perspective of the formulator POSA; is that right?  
 9 A That most of my opinions are involved or  
 10 are focused on formulation aspects of these  
 11 patents. I have other expertise, but, again, as  
 12 part of the POSA team that I proposed, most of my  
 13 opinions are focused on the formulation aspects.  
 14 Q Well, why don't we look at paragraph 28  
 15 of your original report, then, because my  
 16 understanding was that you were holding yourself  
 17 out as the formulator part of the POSA. If you  
 18 could turn to paragraph 28 of Exhibit 1002,  
 19 please.  
 20 If we could turn to paragraph 28 on page  
 21 13. It says numbered page 13. Great.  
 22 Do you see in paragraph 28, you say, "I

Page 359

1 have at least the ordinary skill of the  
 2 'formulator' who forms part of the POSA team  
 3 (i.e., the 'Formulator POSA')"?  
 4 Do you see that?  
 5 A I see that.  
 6 Q Okay. And you didn't take the position  
 7 in your declaration that you were speaking from  
 8 the perspective of somebody other than the  
 9 formulator POSA as you defined it, right?  
 10 A Well, again, the POSA is a -- is a team.  
 11 The people on that team, or the individuals as  
 12 part of that team, bring multitudes of information  
 13 into the team. But, again, yes, I am -- my  
 14 opinions are focused or are primarily specific to  
 15 a formulator on the POSA team.  
 16 Q Okay. You didn't purport to represent  
 17 the entire POSA team, right?  
 18 A No, I don't.  
 19 Q Okay. And -- and let's take a look at  
 20 the Jones declaration, please, Exhibit 2201.  
 21 THE VIDEOGRAPHER: That just got sent to  
 22 me now. Hang on.

Page 360

1 MS. BERNIKER: Okay.

2 BY MS. BERNIKER:

3 Q You're familiar with Dr. Jones'  
4 definition of a POSA, right, Doctor?

5 A I have seen Dr. Jones' definition of a  
6 POSA. I'm going to need to refamiliarize myself  
7 with it.

8 Q Sure. And before I -- before I get to  
9 the details, let me ask you this. You understand  
10 that Dr. Jones also set forth a definition of a  
11 POSA, which is a team of individuals, right?

12 A Again, I need to see it. I don't have  
13 enough recollection of his definition to opine on  
14 it right now.

15 Q Okay. Why don't we take a look at  
16 Dr. Jones' paragraphs 38 through 40.

17 THE VIDEOGRAPHER: It's importing right  
18 now. It's scanning all the pages.

19 MS. BERNIKER: Absolutely.

20 My apologies, Dan, for missing that one.

21 THE VIDEOGRAPHER: No, it's quite all  
22 right. Thank you for letting me get a head start

Page 362

1 BY MS. BERNIKER:

2 Q Certainly.

3 Just like the Nalox-1 POSA definition,  
4 Dr. Jones' definition is also of a POSA team,  
5 right?

6 A Yes.

7 Q And you possess some of the  
8 qualifications of the team, but you don't purport  
9 to possess the qualifications of the entire team,  
10 right?

11 A I don't possess the -- I am a member of  
12 the POSA team proposed in my -- under my  
13 definition of POSA, and I would be a member of the  
14 POSA team as defined by Dr. Jones.

15 Q You don't represent the complete POSA  
16 team defined by Dr. Jones, right?

17 A Again, that's why we -- why the POSA is  
18 defined as a team, so that there can be multiple  
19 members. But I represent a member of the POSA  
20 team based on my definition of a POSA and I would  
21 meet the definition of a member of the POSA team  
22 in Dr. Jones' definition.

Page 361

1 with that. Okay. So, there's Jones, 2201. Let's  
2 pull this up. Okay. Let's exit out of this.  
3 Pull this up now, which everybody should be able  
4 to see this. Okay. That's what we have here.

5 Okay. What page, counsel?

6 MS. BERNIKER: Pages 20 to 21, please.  
7 Not -- I believe they're --

8 THE VIDEOGRAPHER: So 20 and 21, okay.  
9 Doctor, let me --

10 MS. BERNIKER: If you could just give  
11 the doctor the opportunity to take a look at  
12 paragraphs 38 through 40.

13 THE VIDEOGRAPHER: Doctor, let me know  
14 when to flip the page.

15 THE WITNESS: Okay. Thank you.  
16 (Document review.)

17 Okay. Can you flip the page?

18 THE VIDEOGRAPHER: Sure.

19 THE WITNESS: (Document review.)

20 Okay. I've read that and recalled what  
21 the -- Dr. Jones' definition of a POSA is. Is  
22 there a question that you would like me to answer?

Page 363

1 Q Okay. But to be clear, Doctor, you  
2 don't represent the complete POSA team in  
3 Dr. Jones' definition, right?

4 A I represent a member of the POSA team.

5 Q So that's a yes?

6 A I stand by my statement. I represent a  
7 member of the POSA team described by Dr. Jones.

8 Q But not the complete team, right?

9 A You know, POSAs are -- are imaginary  
10 compilations of expertise based on -- and then we  
11 try to overlay individuals on them. I'm a member  
12 of the POSA team as defined by Dr. Jones.

13 Q Are you having trouble with my question?  
14 My question is, you're only part of the team,  
15 right?

16 MR. BERMAN: Objection to form.

17 Q It's a yes or no question. You're part  
18 of the team, not the complete team, right?

19 A By definition of "team," there would be  
20 multiple human members. I would be one of those  
21 human members.

22 Q Because you don't have all of the

3 (Pages 360 to 363)

Page 364

1 qualifications. You have some of them, right?  
 2 A Well, as defined, the POSA is defined as  
 3 a team, a grouping of individuals who have  
 4 expertise. I'm a member of the POSA team as  
 5 defined by both Dr. Jones and by me.  
 6 Q Let's try this again. You have some but  
 7 not all of the qualifications of the POSA team as  
 8 defined by Dr. Jones, right? This should not be a  
 9 hard question.  
 10 MR. BERMAN: Objection to form.  
 11 A Well, again, I'm -- I'm a member of the  
 12 POSA team and I bring my expertise to the POSA  
 13 team. And I recognize that there are other people  
 14 who would bring additional expertise to the team.  
 15 Q Do you or do you not have all of the  
 16 qualifications of the POSA team that Dr. Jones  
 17 sets forth in his declaration?  
 18 A Dr. Jones defines a team, and he chooses  
 19 to pull out specific characteristics of that -- of  
 20 that -- of those team members and separate them  
 21 into individual paragraphs. That's, you know, an  
 22 artificial manner of defining the team, and I,

Page 365

1 again, represent a member of the team who can  
 2 contribute to the POSA team regarding this matter.  
 3 Q Is there some reason you're not  
 4 comfortable testifying that you don't have every  
 5 single one of the qualifications of his POSA team  
 6 even if you just told me five minutes ago that you  
 7 don't have all of the qualifications of your POSA  
 8 team?  
 9 MR. BERMAN: Objection to form.  
 10 A Is there a specific aspect that you want  
 11 to ask about? Again, the POSA team members  
 12 have --  
 13 Q I don't think this is a hard question.  
 14 You've seen the POSA team description. Do you or  
 15 do you not have all of the qualifications of that  
 16 team?  
 17 A I have the qualifications.  
 18 Q You personally.  
 19 A I have the qualifications to be a member  
 20 of the POSA team.  
 21 Q But you don't represent the entire POSA,  
 22 in terms of experience, right?

Page 366

1 A Well, the POSA has already been defined  
 2 as a team.  
 3 Q So why can't you just answer me yes, I  
 4 do not?  
 5 A There's multiple individuals who are  
 6 part of that team who contribute aspects to the  
 7 team.  
 8 Q This is going to be a really long day if  
 9 I can't get a clean answer to a very basic  
 10 question so let's make it simpler.  
 11 Look at paragraph 40 in front of you.  
 12 Among the things in Dr. Jones' definition, "the  
 13 POSA team would include a medical practitioner  
 14 and, thus, would have had knowledge regarding the  
 15 administration of opioid antagonists to treat  
 16 opioid overdoses by medically trained personnel,  
 17 first responders, and others in the community, and  
 18 would have had clinical experience with  
 19 administering opioid antagonists to overdose  
 20 patients."  
 21 Do you see that?  
 22 A I see that.

Page 367

1 Q You're not a medical practitioner who  
 2 has had clinical experience administering opioid  
 3 overdoses -- opioid antagonists to overdose  
 4 patients, right, Doctor?  
 5 A As stated in that paragraph, there are  
 6 aspects of the definition in that paragraph that I  
 7 do not have -- I'm not a medically -- well, I --  
 8 I'm a biomedically trained person, but, again, I  
 9 have stated I do not have a license to practice  
 10 medicine so I have not had the ability to directly  
 11 treat patients, but I have many of the other  
 12 understandings of the POSA being defined in this  
 13 paragraph.  
 14 Q One of the things that's required here  
 15 is clinical experience with administering opioid  
 16 antagonists to overdose patients, right?  
 17 A I have not had clinical experience  
 18 administering opioid antagonists to overdose  
 19 patients.  
 20 Q Okay. So it is not fair to say that you  
 21 have all of the qualifications of a POSA under  
 22 Dr. Jones' definition, right?

Page 368

1 MR. BERMAN: Objection to form.

2 A Again, I -- I have said repeatedly, I  
3 don't have a license to practice medicine. I have  
4 agreed that I don't have clinical experience with  
5 administering opioid antagonists to overdose  
6 patients, but I am qualified to be a member of the  
7 POSA team as defined by Dr. Jones.

8 Q Okay. I would like you to direct your  
9 attention, please, to your supplemental  
10 declaration, Exhibit 1201, please. And if we  
11 could take a look at footnote 1 on page 6.

12 THE VIDEOGRAPHER: Okay. One second.  
13 1201, supplemental.

14 MS. BERNIKER: If we could pull up  
15 footnote 1, please.

16 BY MS. BERNIKER:

17 Q This is your supplemental declaration  
18 that you submitted in this case, right, Doctor?

19 A It appears to be, yes.

20 Q I want to look at the very last sentence  
21 of this footnote. You say, "Nevertheless, I have  
22 the qualifications of a POSA under Dr. Jones' and

Page 370

1 that team.

2 Q Even when you're referring to the  
3 qualifications that you possess among that team?

4 MR. BERMAN: Objection to form.

5 A Again, I am a member of the POSA team.

6 Q Were you trying to represent to the  
7 patent office here that you had all of the -- all  
8 of the qualifications of Dr. Jones' POSA?

9 A In -- in my earlier statements, and even  
10 in Dr. Jones' definition, he describes a POSA  
11 team, and I meet the qualifications of a member of  
12 the POSA team.

13 Q Were you trying to represent to the  
14 patent office that you met all of the  
15 qualifications of the POSA team under Dr. Jones'  
16 definition?

17 A The statement as given in this footnote  
18 is that I have the qualifications of a member of a  
19 POSA team.

20 Q I don't see the word "member" --

21 A Dr. Jones --

22 Q -- or "team."

Page 369

1 Dr. Williams' definitions."

2 Do you see that?

3 A I see that.

4 Q Do you believe that's a fully accurate  
5 sentence, Doctor?

6 A I -- I expect in the same way the term  
7 "POSA" has been used throughout my report, yes,  
8 that I'm a member of the POSA team. We -- I did  
9 not write "POSA team" in all of the references to  
10 "POSA" in my reports, and so I stand by that. I  
11 have the qualifications as a member of the POSA  
12 team under Dr. Jones' and Dr. Williams'  
13 definitions.

14 Q You don't think it would have been more  
15 accurate to say I have some of the qualifications  
16 of a POSA team under Dr. Jones' and Dr. Williams'  
17 definitions?

18 A There -- there may have been other ways  
19 of stating this when I -- but, typically, when I  
20 am writing reports, the POSA is, in general,  
21 defined as a team, and it's been my general habit  
22 to just use the term "POSA" when I'm referring to

Page 371

1 A -- defined it -- defined the POSA as a  
2 team.

3 Q Where does it say member and team in the  
4 sentence?

5 A It does not say member and team in the  
6 sentence.

7 Q What it says is "I have the  
8 qualifications of a POSA," not part of the POSA or  
9 a member of the POSA, right?

10 A The POSA is defined as a team --

11 Q Do you think --

12 A -- and --

13 Q Do you think that it was irrelevant for  
14 purposes of this footnote whether or not you had  
15 clinical experience in administering opioid  
16 overdose -- I'm sorry, in administering naloxone  
17 to opioid overdose patients?

18 A I'm going to have to read the section of  
19 my report that this footnote refers to.

20 Q Sure. Go ahead.

21 If we could just zoom out so the doctor  
22 can see the entire source for the footnote.

5 (Pages 368 to 371)

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.